





# Study Designs in Clinical Epidemiology

Mirjam Nilsson



## The Role of Study Design

- **Core Question:** How do we measure the impact of an exposure (risk factor, treatment) on an outcome (disease, cure)?
- **Study Design is the Blueprint:** It dictates the reliability and validity of the findings.
- **Hierarchy of Evidence:** The design determines its position on the evidence pyramid—from generating hypotheses to proving causality.



## Observational Studies (Defined)

- **Definition:** The investigator **observes** nature without intervening or controlling the exposure.
- **Purpose:** Identifying potential risk factors, determining disease incidence and prevalence, and generating hypotheses.
- **Limitation:** **Cannot prove causality** definitively, as confounding factors may influence the results.

## Type 1: Cross-Sectional Studies

- **Design:** Measures both exposure and outcome **at a single point in time** (like a snapshot).
- **Key Measure: Prevalence** (the proportion of existing cases).
- **Strengths:** Quick, inexpensive, good for determining the burden of disease.
- **Weakness:** Cannot establish a temporal sequence (which came first: the exposure or the disease?).
- *Example:* Surveying a large population to find the current prevalence of smoking and hypertension simultaneously.

## Type 2: Case-Control Studies

- **Design: Retrospective** (looking backward). Investigators start with the **outcome (disease)** and look back to determine past **exposure**.
- **Groups: Cases** (with the disease) and **Controls** (without the disease).
- **Key Measure: Odds Ratio (OR)**.
- **Strengths:** Efficient for **rare diseases**; can study multiple potential exposures.
- **Weakness:** Highly susceptible to **Recall Bias** (cases may remember exposures differently than controls) and **Selection Bias** (choosing the wrong controls).

## Type 3: Cohort Studies

- **Design: Prospective** (looking forward, though sometimes done retrospectively using existing records). Investigators start with the **exposure** and follow groups over time to see who develops the **outcome**.
- **Groups: Exposed** (e.g., healthcare workers) and **Unexposed** (e.g., non-healthcare workers).
- **Key Measure: Incidence** and **Relative Risk (RR)**.
- **Strengths:** Establishes a clear **temporal sequence** (exposure precedes outcome); good for rare exposures.
- **Weakness:** Expensive and time-consuming; poor for **rare diseases**; susceptible to **Loss to Follow-up**.

## Conclusion & Takeaways

- **Design Dictates Evidence:** The type of clinical question determines the appropriate study design.
- **For Etiology/Risk:** Cohort studies offer the best observational evidence.
- **For Therapy/Efficacy:** RCTs are required to prove a treatment works.
- **Critical Appraisal is Key:** Clinicians must understand the study design to correctly interpret the strength and applicability of the findings.

